FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
BASINGSTOKE, England and PHILADELPHIA, April 23 /PRNewswire/ --
- Within the First Eight Months Since its Introduction in the United States, VYVANSE has Achieved Over One Million Prescriptions
- In…